Table 2.
Comparison of patients based on CLZ treatment outcome.
| Variables | CLZ discontinued at follow-up (n = 14) | CLZ continued at follow-up (n = 45) | p Value |
|---|---|---|---|
| n (%) | n (%) | ||
| Age, mean ± SD, y | 46.4 ± 14.2 | 39.4 ± 14.7 | 0.200 |
| Gender | |||
| Male | 8 (80) | 28 (74) | 1.000 |
| Female | 2 (20) | 10 (26) | |
| Ethnicity | |||
| Caucasian | 7 (78) | 20 (80) | 1.000 |
| Non-Caucasian | 2 (22) | 5 (20) | |
| Main diagnosis | |||
| Schizophrenia | 13 (93) | 44 (98) | 0.421 |
| Other | 1 (7) | 1 (2) | |
| Time to first neutropenia, mean ± SD, y | 3.0 ± 4.4 | 5.3 ± 7.7 | 0.334 |
| ⩽1 year, n (%) | 7 (58) | 18 (60) | 1.000 |
| >1 year, n (%) | 5 (42) | 12 (40) | |
| ANC nadir at first neutropenia, mean ± SD, ×109 cells/L | 1.12 ± 0.28 | 0.90 ± 0.43 | 0.109 |
| ⩽1.00 × 109 cells/L | 5 (46) | 13 (52) | 0.717 |
| >1.00 × 109 cells/L | 6 (54) | 12 (48) | |
| CLZ dose at first neutropenia, mean ± SD, mg/d | 404 ± 142 | 333 ± 172 | 0.334 |
| Time to second neutropenia, mean ± SD, y | 0.7 ± 1.2 | 0.3 ± 0.5 | 0.357 |
| Delay shorter than first neutropenia | 3 (27) | 6 (32) | 1.000 |
| Delay longer or equal to first neutropenia | 8 (73) | 13 (68) | |
| ANC nadir at second neutropenia, mean ± SD, ×109 cells/L | 0.87 ± 0.47 | 0.71 ± 0.56 | 0.502 |
| ANC nadir lower than at first neutropenia | 3 (43) | 3 (19) | 0.318 |
| ANC nadir higher or equal to first neutropenia | 4 (57) | 13 (81) | |
| Number of neutropenia episodes prior to CSF initiation, mean ± SD | 1.9 ± 0.9 | 2.0 ± 1.2 | 0.933 |
| Number of neutropenia episodes following CSF initiation, mean ± SD | 1.7 ± 1.9 | 0.9 ± 1.8 | 0.234 |
| CSF administration strategy | |||
| As-needed | 5 (50) | 21 (51) | 1.000 |
| Prophylactic | 5 (50) | 20 (49) | |
| Concomitant lithium use | 6 (75) | 9 (41) | 0.215 |
| Follow-up, mean ± SD, y | 2.6 ± 3.3 | 1.7 ± 1.8 | 0.501 |
ANC: absolute neutrophil count; CSF: colony-stimulating factor; d: day; L: litre; mg: milligram; SD: standard deviation; y: year.